Make one post in the community_老虎社区_美港股上老虎

2021-05-26

Make one post in the community. Please like and comment. Thanks.

Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":136381616,"tweetId":"136381616","gmtCreate":1621994504335,"gmtModify":1631883989297,"author":{"id":3578111487107537,"idStr":"3578111487107537","authorId":3578111487107537,"authorIdStr":"3578111487107537","name":"Chimpsey","avatar":"https://static.tigerbbs.com/ab58cb989ba2205bb2646f1c4d97c579","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":29,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Make one post in the community. Please like and comment. Thanks.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Make one post in the community. Please like and comment. Thanks.&nbsp;</p></body></html>","text":"Make one post in the community. Please like and comment. Thanks.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/136381616","repostId":1191037526,"repostType":4,"repost":{"id":"1191037526","kind":"news","pubTimestamp":1621994290,"share":"https://www.laohu8.com/m/news/1191037526?lang=&edition=full","pubTime":"2021-05-26 09:58","market":"us","language":"en","title":"Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?","url":"https://stock-news.laohu8.com/highlight/detail?id=1191037526","media":"Motley Fool","summary":"Pfizer(NYSE:PFE) stated earlier this month that it expects its COVID-19 vaccine will generate sales ","content":"<p><b>Pfizer</b>(NYSE:PFE)&nbsp;stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. More revenue is on the way beyond 2021. For example, Pfizer and its partner<b>BioNTech</b>(NASDAQ:BNTX)recently announced a new deal with the European Union tosupply up to 1.8 billion additional dosesthrough 2023.</p>\n<p>However, the dynamics of the COVID-19 vaccine market are constantly changing. Last week, researchers in Spain reported results from a clinical study that included Pfizer's COVID-19 vaccine. Could these results be bad news for future sales of Pfizer's vaccine?</p>\n<p><img src=\"https://static.tigerbbs.com/5ae75aadcdda23603ea8f59dda16c30a\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p><b>A mix-and-match milestone</b></p>\n<p>Scientists have wondered what would happen if the initial dose of one COVID-19 vaccine was followed by a second dose from another vaccine. A few so-called \"mix-and-match\" clinical studies have been undertaken to find the answer. On May 18, the first results from one of those studies were announced.</p>\n<p>Researchers at the Carlos III Health Institute in Spain recruited participants for the CombiVacS clinical study who had received only a single dose of<b>AstraZeneca</b>'s(NASDAQ:AZN)vaccine within the previous eight weeks. Instead of administering the second dose of AstraZeneca's vaccine, the Spanish team gave the participants Pfizer's and BioNTech's COVID-19 vaccine instead.</p>\n<p>What happened? Participants receiving a first dose of the AstraZeneca vaccine followed by a second dose of the Pfizer vaccine experienced immune system responses that were \"greatly enhanced.\" The researchers reported that antibody levels for this group were at least 40 times higher than for individuals who only received a single dose of AstraZeneca's vaccine. These antibody levels were also higher than those reported for individuals who received two doses of the Pfizer vaccine.</p>\n<p>Side effects were similar to those observed in the past with the Pfizer vaccine. There were no adverse effects that required special medical attention or hospitalization. The most common side effects were headache, malaise, nausea, cough, and fever, most of which were mild cases.</p>\n<p><b>Bad for Pfizer?</b></p>\n<p>It's easy to see how these mix-and-match results might negatively impact the sales of Pfizer's vaccine. If a combination of one dose of the AstraZeneca vaccine with a second dose of the Pfizer vaccine is more effective than two doses of the Pfizer vaccine, governments could want to take this approach. In theory, that could slash Pfizer's sales in half.</p>\n<p>But don't put the cart before the horse: The Spanish clinical study hasn't been peer-reviewed yet. Also, the study itself was relatively small -- only 673 people in total, with 443 receiving the mix-and-match doses and 232 only receiving the first AstraZeneca dose.</p>\n<p>The European Union isn't likely to want to go with a mix of AstraZeneca and Pfizer vaccines, however. The EU issuing AstraZenecaover allegedly failing to meet its supply commitments. This dispute played a major role in Pfizer and BioNTech winning a big supply deal that covers the next couple of years.</p>\n<p>Even if the findings made by the Spanish researchers are eventually confirmed, it could still be too late to make much of a difference. There's a good chance that in future, only single-dose annual vaccinations will be required. If that's the case, any advantages offered by a two-dose regimen, including one combining AstraZeneca's and Pfizer's vaccines, could be irrelevant.</p>\n<p><b>What really matters</b></p>\n<p>Results from the mix-and-match studies probably won't present major problems for Pfizer (or for any of the other leading vaccine makers, for that matter). What really matters for the company is how frequently booster doses will be needed.</p>\n<p>The answer to that question probably won't be answered until sometime this fall. Meanwhile, investors appear to be discounting the likelihood that Pfizer will be able to count on huge recurring revenue for years to come: The bigpharma stocktrades at only around 12 times expected earnings. Should COVID-19 vaccines be needed at least once per year from here on out, Pfizer could be viewed, in retrospect, as a bargain at its current price.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould This Study Be Bad News for Pfizer's COVID Vaccine Sales?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 09:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/25/could-this-study-be-bad-news-pfizers-covid-vaccine/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer(NYSE:PFE) stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. More revenue is on the way beyond 2021. For example, Pfizer and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/25/could-this-study-be-bad-news-pfizers-covid-vaccine/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/05/25/could-this-study-be-bad-news-pfizers-covid-vaccine/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191037526","content_text":"Pfizer(NYSE:PFE) stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. More revenue is on the way beyond 2021. For example, Pfizer and its partnerBioNTech(NASDAQ:BNTX)recently announced a new deal with the European Union tosupply up to 1.8 billion additional dosesthrough 2023.\nHowever, the dynamics of the COVID-19 vaccine market are constantly changing. Last week, researchers in Spain reported results from a clinical study that included Pfizer's COVID-19 vaccine. Could these results be bad news for future sales of Pfizer's vaccine?\n\nIMAGE SOURCE: GETTY IMAGES.\nA mix-and-match milestone\nScientists have wondered what would happen if the initial dose of one COVID-19 vaccine was followed by a second dose from another vaccine. A few so-called \"mix-and-match\" clinical studies have been undertaken to find the answer. On May 18, the first results from one of those studies were announced.\nResearchers at the Carlos III Health Institute in Spain recruited participants for the CombiVacS clinical study who had received only a single dose ofAstraZeneca's(NASDAQ:AZN)vaccine within the previous eight weeks. Instead of administering the second dose of AstraZeneca's vaccine, the Spanish team gave the participants Pfizer's and BioNTech's COVID-19 vaccine instead.\nWhat happened? Participants receiving a first dose of the AstraZeneca vaccine followed by a second dose of the Pfizer vaccine experienced immune system responses that were \"greatly enhanced.\" The researchers reported that antibody levels for this group were at least 40 times higher than for individuals who only received a single dose of AstraZeneca's vaccine. These antibody levels were also higher than those reported for individuals who received two doses of the Pfizer vaccine.\nSide effects were similar to those observed in the past with the Pfizer vaccine. There were no adverse effects that required special medical attention or hospitalization. The most common side effects were headache, malaise, nausea, cough, and fever, most of which were mild cases.\nBad for Pfizer?\nIt's easy to see how these mix-and-match results might negatively impact the sales of Pfizer's vaccine. If a combination of one dose of the AstraZeneca vaccine with a second dose of the Pfizer vaccine is more effective than two doses of the Pfizer vaccine, governments could want to take this approach. In theory, that could slash Pfizer's sales in half.\nBut don't put the cart before the horse: The Spanish clinical study hasn't been peer-reviewed yet. Also, the study itself was relatively small -- only 673 people in total, with 443 receiving the mix-and-match doses and 232 only receiving the first AstraZeneca dose.\nThe European Union isn't likely to want to go with a mix of AstraZeneca and Pfizer vaccines, however. The EU issuing AstraZenecaover allegedly failing to meet its supply commitments. This dispute played a major role in Pfizer and BioNTech winning a big supply deal that covers the next couple of years.\nEven if the findings made by the Spanish researchers are eventually confirmed, it could still be too late to make much of a difference. There's a good chance that in future, only single-dose annual vaccinations will be required. If that's the case, any advantages offered by a two-dose regimen, including one combining AstraZeneca's and Pfizer's vaccines, could be irrelevant.\nWhat really matters\nResults from the mix-and-match studies probably won't present major problems for Pfizer (or for any of the other leading vaccine makers, for that matter). What really matters for the company is how frequently booster doses will be needed.\nThe answer to that question probably won't be answered until sometime this fall. Meanwhile, investors appear to be discounting the likelihood that Pfizer will be able to count on huge recurring revenue for years to come: The bigpharma stocktrades at only around 12 times expected earnings. Should COVID-19 vaccines be needed at least once per year from here on out, Pfizer could be viewed, in retrospect, as a bargain at its current price.","news_type":1},"isVote":1,"tweetType":1,"viewCount":99,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MKFG","AONE.U"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":54,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/136381616"}